Corticotropin releasing factor and drug seeking in substance use disorders: Preclinical evidence and translational limitations

The neuropeptide, corticotropin releasing factor (CRF), has been an enigmatic target for the development of medications aimed at treating stress-related disorders. Despite a large body of evidence from preclinical studies in rodents demonstrating that CRF receptor antagonists prevent stressor-induce...

Descripción completa

Detalles Bibliográficos
Autor principal: Mantsch, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757758/
https://www.ncbi.nlm.nih.gov/pubmed/36531188
http://dx.doi.org/10.1016/j.addicn.2022.100038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757758/
https://www.ncbi.nlm.nih.gov/pubmed/36531188
http://dx.doi.org/10.1016/j.addicn.2022.100038

Ejemplares similares